Business
The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.
FEATURED STORIES
PitchBook’s 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026.
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
While treatments exist to manage the symptoms of the disease, nothing has proven to be curative – yet. Several biopharma companies are working hard to change that.
Vivek Ramaswamy is launching a book that represents the social injustice in society. Read the article to get some information about the book and its author.
Codiak has two engineered exosome programs in Phase I, each showing different types of engineering possibilities to deliver targeted payloads that pharmaceutical companies haven’t managed to push all the way through the clinic.
There was plenty of clinical trial updates last week. Here’s a look.
Viatris executive chairman Robert Coury said that seeking new stewards for the site is the best route to ensure that people will have jobs and that the property would remain useful.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Aubrey de Grey has been accused by two women of predatory behavior, an allegation de Grey denies. SENS has placed him on administrative leave pending further investigation.
Republican Senator Rand Paul is under fire from government watchdogs for failing to properly disclose a $15,000 purchase of Gilead Sciences stock made by his wife last year.
Antheia has joined forces with Ginkgo Bioworks to strengthen its efforts in developing and producing essential medicines to treat a wide range of diseases.
Artiva Biotherapeutics is quadrupling its footprint in San Diego with a 52,000 square-foot corporate HQ, R&D and manufacturing center opening next year.